Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease
Liver International · 2024-02 · 44 (2) · 389-398
DOI: 10.1111/liv.15787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 16.11.2023. Verfasst von Deepika Suresh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Hemochromatosis, Fatty Liver. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background & Aims Ferritin has been investigated as a biomarker for liver fibrosis and iron in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). However, whether metabolic hyperferritinaemia predicts progression of liver disease remains unknown. In this study, we sought to understand associations between hyperferritinaemia and (1) adverse clinical outcomes and (2) common genetic variants related to iron metabolism and liver fibrosis.
Methods
This was a retrospective analysis of adults with MASLD seen at the University of Michigan Health System, where MASLD was defined by hepatic steatosis on imaging, biopsy or vibration‐controlled transient elastography, plus metabolic risk factors in the absence of chronic liver diseases other than hemochromatosis. The primary predictor was serum ferritin level, which was dichotomized based on a cut‐off of 300 or 450 mcg/L for women or men. Primary outcomes included (1) incident cirrhosis, liver‐related events, congestive heart failure (CHF), and mortality and (2) distribution of common genetic variants associated with hepatic fibrosis and hereditary hemochromatosis.
Results
Of 7333 patients with MASLD, 1468 (20%) had elevated ferritin. In multivariate analysis, ferritinaemia was associated with increased mortality (HR 1.68 [1.35–2.09], p < .001) and incident liver‐related events (HR 1.92 [1.11–3.32], p = .019). Furthermore, elevated ferritin was associated with carriage of cirrhosis‐promoting alleles including PNPLA3 ‐rs738409‐G allele ( p = .0068) and TM6SF2 ‐rs58542926‐T allele ( p = 0.0083) but not with common HFE mutations.
Conclusions
In MASLD patients, metabolic hyperferritinaemia was associated with increased mortality and higher incidence of liver‐related events, and cirrhosis‐promoting alleles but not with iron overload‐promoting HFE mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Deepika Suresh, Karn Wijarnpreecha, Vincent L Chen
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Suresh, D., Li, A., Miller, M. J., Wijarnpreecha, K., & Chen, V. L. (2024). Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease. Liver International, 44(2), 389-398. https://doi.org/10.1111/liv.15787
Vancouver
Suresh D, Li A, Miller MJ, Wijarnpreecha K, Chen VL. Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease. Liver International. 2024;44(2):389-398. doi:10.1111/liv.15787
BibTeX
@article{Suresh2024,
author = {Suresh, Deepika and Li, Ashley and Miller, Matthew J and Wijarnpreecha, Karn and Chen, Vincent L},
title = {Associations between metabolic hyperferritinaemia, fibrosis‐promoting alleles and clinical outcomes in steatotic liver disease},
journal = {Liver International},
year = {2024},
volume = {44},
number = {2},
pages = {389--398},
doi = {10.1111/liv.15787}
}
EUVIMED